301 related articles for article (PubMed ID: 11894004)
1. Novel gemcitabine-containing triplets in the management of urothelial cancer.
Hussain M; Vaishampayan U; Smith DC
Semin Oncol; 2002 Feb; 29(1 Suppl 3):20-4. PubMed ID: 11894004
[TBL] [Abstract][Full Text] [Related]
2. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine doublets in advanced urothelial cancer.
Stadler WM
Semin Oncol; 2002 Feb; 29(1 Suppl 3):15-9. PubMed ID: 11894003
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
[TBL] [Abstract][Full Text] [Related]
6. New chemotherapy combinations for advanced bladder cancer.
Bellmunt J; Albiol S
Curr Opin Urol; 2001 Sep; 11(5):517-22. PubMed ID: 11493774
[TBL] [Abstract][Full Text] [Related]
7. Combined systemic therapy and radiotherapy for bladder cancer.
Rödel C; Weiss C; Sauer R
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():29-31. PubMed ID: 18167005
[No Abstract] [Full Text] [Related]
8. Systemic chemotherapy of transitional cell carcinoma of the urothelium.
Brinkley WM; Torti FM
Semin Surg Oncol; 1997; 13(5):365-75. PubMed ID: 9259093
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
von der Maase H; Sengelov L; Roberts JT; Ricci S; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
J Clin Oncol; 2005 Jul; 23(21):4602-8. PubMed ID: 16034041
[TBL] [Abstract][Full Text] [Related]
11. [New developments in chemotherapy for metastasized bladder cancer].
de Wit R
Ned Tijdschr Geneeskd; 2001 Dec; 145(50):2412-7. PubMed ID: 11776665
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Halim A; Abotouk N
Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Albanell J; Tabernero JM; Cortés-Funes H; Baselga J
Eur J Cancer; 2000 Jul; 36 Suppl 2():17-25. PubMed ID: 10908844
[TBL] [Abstract][Full Text] [Related]
14. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
15. [Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer].
Asadauskiene J; Aleknavicius E; Zelviene TP; Jankevicius F
Medicina (Kaunas); 2006; 42(10):781-7. PubMed ID: 17090976
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and cisplatin for advanced, metastatic bladder cancer.
Cohen MH; Rothmann M
J Clin Oncol; 2001 Feb; 19(4):1229-31. PubMed ID: 11181690
[No Abstract] [Full Text] [Related]
17. The role of taxanes in the management of bladder cancer.
Galsky MD
Oncologist; 2005; 10(10):792-8. PubMed ID: 16314289
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
[TBL] [Abstract][Full Text] [Related]
19. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
Ichioka D; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Nishiyama H
Jpn J Clin Oncol; 2015 Sep; 45(9):867-73. PubMed ID: 26056328
[TBL] [Abstract][Full Text] [Related]
20. Second-line treatment of advanced transitional cell carcinoma of the urothelial tract.
Sternberg CN
Curr Opin Urol; 2001 Sep; 11(5):523-9. PubMed ID: 11493775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
